![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SBDS |
Gene summary for SBDS |
![]() |
Gene information | Species | Human | Gene symbol | SBDS | Gene ID | 51119 |
Gene name | SBDS ribosome maturation factor | |
Gene Alias | CGI-97 | |
Cytomap | 7q11.21 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | A0A0S2Z5I7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51119 | SBDS | CA_HPV_1 | Human | Cervix | CC | 3.30e-09 | -1.97e-01 | 0.0264 |
51119 | SBDS | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 2.67e-03 | -2.77e-01 | 0.0208 |
51119 | SBDS | CCI_1 | Human | Cervix | CC | 3.22e-02 | -4.90e-01 | 0.528 |
51119 | SBDS | CCI_3 | Human | Cervix | CC | 1.78e-06 | -5.39e-01 | 0.516 |
51119 | SBDS | CCII_1 | Human | Cervix | CC | 1.60e-14 | -5.70e-01 | 0.3249 |
51119 | SBDS | HTA11_78_2000001011 | Human | Colorectum | AD | 2.72e-09 | 5.23e-01 | -0.1088 |
51119 | SBDS | HTA11_347_2000001011 | Human | Colorectum | AD | 2.27e-06 | 4.55e-01 | -0.1954 |
51119 | SBDS | HTA11_696_2000001011 | Human | Colorectum | AD | 2.64e-02 | 2.73e-01 | -0.1464 |
51119 | SBDS | HTA11_866_2000001011 | Human | Colorectum | AD | 3.66e-02 | 1.06e-01 | -0.1001 |
51119 | SBDS | HTA11_2992_2000001011 | Human | Colorectum | SER | 5.85e-03 | 6.53e-01 | -0.1706 |
51119 | SBDS | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.53e-08 | 4.21e-01 | 0.294 |
51119 | SBDS | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.00e-17 | 9.61e-01 | 0.281 |
51119 | SBDS | HTA11_99999971662_82457 | Human | Colorectum | MSS | 7.03e-15 | 5.07e-01 | 0.3859 |
51119 | SBDS | HTA11_99999974143_84620 | Human | Colorectum | MSS | 9.51e-05 | 2.55e-01 | 0.3005 |
51119 | SBDS | A002-C-201 | Human | Colorectum | FAP | 8.62e-04 | -9.51e-02 | 0.0324 |
51119 | SBDS | AEH-subject1 | Human | Endometrium | AEH | 1.91e-04 | -1.90e-01 | -0.3059 |
51119 | SBDS | AEH-subject2 | Human | Endometrium | AEH | 2.90e-09 | -1.89e-01 | -0.2525 |
51119 | SBDS | AEH-subject3 | Human | Endometrium | AEH | 9.43e-04 | -2.21e-01 | -0.2576 |
51119 | SBDS | EEC-subject1 | Human | Endometrium | EEC | 6.29e-10 | -2.56e-01 | -0.2682 |
51119 | SBDS | EEC-subject2 | Human | Endometrium | EEC | 1.25e-08 | -2.71e-01 | -0.2607 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004225510 | Cervix | CC | ribosome assembly | 25/2311 | 61/18723 | 1.70e-08 | 1.27e-06 | 25 |
GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
GO:00305957 | Cervix | CC | leukocyte chemotaxis | 57/2311 | 230/18723 | 1.48e-07 | 7.07e-06 | 57 |
GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
GO:004225410 | Cervix | CC | ribosome biogenesis | 62/2311 | 299/18723 | 2.48e-05 | 4.27e-04 | 62 |
GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
GO:00022443 | Cervix | CC | hematopoietic progenitor cell differentiation | 26/2311 | 114/18723 | 1.30e-03 | 1.03e-02 | 26 |
GO:00015037 | Cervix | CC | ossification | 71/2311 | 408/18723 | 1.67e-03 | 1.28e-02 | 71 |
GO:0031214 | Cervix | CC | biomineral tissue development | 32/2311 | 169/18723 | 8.73e-03 | 4.48e-02 | 32 |
GO:00160727 | Cervix | CC | rRNA metabolic process | 42/2311 | 236/18723 | 9.12e-03 | 4.60e-02 | 42 |
GO:0030282 | Cervix | CC | bone mineralization | 24/2311 | 119/18723 | 1.00e-02 | 4.89e-02 | 24 |
GO:0110148 | Cervix | CC | biomineralization | 32/2311 | 171/18723 | 1.04e-02 | 4.97e-02 | 32 |
GO:004225515 | Cervix | HSIL_HPV | ribosome assembly | 20/737 | 61/18723 | 8.44e-14 | 2.03e-10 | 20 |
GO:002261315 | Cervix | HSIL_HPV | ribonucleoprotein complex biogenesis | 52/737 | 463/18723 | 9.85e-12 | 6.81e-09 | 52 |
GO:004225415 | Cervix | HSIL_HPV | ribosome biogenesis | 40/737 | 299/18723 | 1.25e-11 | 6.81e-09 | 40 |
GO:006032612 | Cervix | HSIL_HPV | cell chemotaxis | 36/737 | 310/18723 | 6.69e-09 | 8.80e-07 | 36 |
GO:003059512 | Cervix | HSIL_HPV | leukocyte chemotaxis | 29/737 | 230/18723 | 3.25e-08 | 2.70e-06 | 29 |
GO:005090012 | Cervix | HSIL_HPV | leukocyte migration | 38/737 | 369/18723 | 6.67e-08 | 4.59e-06 | 38 |
GO:00063647 | Cervix | HSIL_HPV | rRNA processing | 27/737 | 225/18723 | 2.67e-07 | 1.55e-05 | 27 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SBDS | SNV | Missense_Mutation | novel | c.482N>C | p.Leu161Ser | p.L161S | Q9Y3A5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SBDS | SNV | Missense_Mutation | novel | c.302N>G | p.His101Arg | p.H101R | Q9Y3A5 | protein_coding | tolerated(0.14) | benign(0.065) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SBDS | SNV | Missense_Mutation | rs796954165 | c.698C>A | p.Ser233Tyr | p.S233Y | Q9Y3A5 | protein_coding | tolerated(0.86) | benign(0.011) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SBDS | SNV | Missense_Mutation | novel | c.574N>T | p.Pro192Ser | p.P192S | Q9Y3A5 | protein_coding | tolerated(0.45) | benign(0.042) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
SBDS | insertion | Frame_Shift_Ins | novel | c.515_516insCCCAGCTACTCAA | p.Met172IlefsTer15 | p.M172Ifs*15 | Q9Y3A5 | protein_coding | TCGA-D1-A0ZR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SBDS | insertion | Frame_Shift_Ins | novel | c.513_514insGCCTGTA | p.Met172AlafsTer13 | p.M172Afs*13 | Q9Y3A5 | protein_coding | TCGA-D1-A0ZR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SBDS | SNV | Missense_Mutation | c.133N>G | p.Lys45Glu | p.K45E | Q9Y3A5 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-50-6592-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SBDS | SNV | Missense_Mutation | novel | c.264G>C | p.Leu88Phe | p.L88F | Q9Y3A5 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-56-A5DR-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SBDS | SNV | Missense_Mutation | c.592N>C | p.Glu198Gln | p.E198Q | Q9Y3A5 | protein_coding | deleterious(0.01) | possibly_damaging(0.706) | TCGA-77-7141-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SBDS | SNV | Missense_Mutation | c.487G>C | p.Glu163Gln | p.E163Q | Q9Y3A5 | protein_coding | tolerated(0.11) | benign(0.301) | TCGA-CV-7102-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |